James S L, DeBlois L A
J Immunol. 1986 May 15;136(10):3864-71.
The efficacy of a new vaccination procedure against Schistosoma mansoni, involving intradermal injection of nonliving antigen combined with the bacterial adjuvant Mycobacterium bovis strain bacillus Calmette Guérin, was tested in several strains of mice. Development of protection against subsequent infection was compared with in vivo skin test reactivity and in vitro humoral reactivity to soluble and surface-associated schistosome antigens. Significant levels of resistance and immune response were displayed by many inbred mouse strains, including C57BL/6J, C3H/HeN, and CBA/J, as well as outbred Swiss-Webster mice. However, no definite correlation was observed between the level of any particular immune response and the level of resistance to challenge S. mansoni infection. Development of protective immunity was also examined in mice with various immune defects, to determine whether these responses are relevant to resistance in this model. Animals with defective specific immediate hypersensitivity response due to deficiencies in IgE (SJL/J) or mast cell (W/Wv) production displayed strong resistance as a result of immunization. Likewise, mice bearing the lpsd (C3H/HeJ) or xid (CBA/N) mutations, affecting cellular or humoral response to certain thymus-independent antigens, developed significant levels of resistance after immunization. A/J mice, with defects in cellular recognition of bacterial endotoxin as well as deficiencies in natural killer cell activity and complement function, also showed significant protective immunity. Thus, these reactivities do not appear to be essential to the resistance against S. mansoni induced by the nonliving vaccine. Two nonresponder strains were identified, P and BALB/c. P mice were defective in specific delayed hypersensitivity response as well as resistance to infection. However, BALB/c mice showed no obvious immune deficiencies at the time of challenge. These results agreed with previous findings in mice immunized by exposure to radiation-attenuated cercariae with one exception; BALB/c mice were protected by vaccination with irradiated cercariae but not by the nonliving vaccine. Thus, further examination of immune response in mice identified in this study as high and low responder strains should allow characterization of critical immune resistance mechanisms induced by the nonliving vaccine, as well as immune mechanisms operating in common between these two models of resistance to S. mansoni.
一种针对曼氏血吸虫的新疫苗接种程序,包括皮内注射无活性抗原并联合细菌佐剂卡介苗(Mycobacterium bovis strain bacillus Calmette Guérin),在多个品系的小鼠中进行了测试。将针对后续感染的保护作用的发展情况与体内皮肤试验反应性以及对可溶性和表面相关血吸虫抗原的体外体液反应性进行了比较。许多近交系小鼠品系,包括C57BL/6J、C3H/HeN和CBA/J,以及远交系瑞士韦伯斯特小鼠,都表现出显著水平的抗性和免疫反应。然而,在任何特定免疫反应的水平与对曼氏血吸虫攻击感染的抗性水平之间未观察到明确的相关性。还在具有各种免疫缺陷的小鼠中检查了保护性免疫的发展情况,以确定这些反应是否与该模型中的抗性相关。由于IgE(SJL/J)或肥大细胞(W/Wv)产生缺陷而具有特异性速发型超敏反应缺陷的动物,免疫后表现出强烈的抗性。同样,携带影响对某些非胸腺依赖性抗原的细胞或体液反应的lpsd(C3H/HeJ)或xid(CBA/N)突变的小鼠,免疫后也产生了显著水平的抗性。A/J小鼠在细菌内毒素的细胞识别方面存在缺陷,并且自然杀伤细胞活性和补体功能也存在缺陷,但也表现出显著的保护性免疫。因此,这些反应似乎对于无活性疫苗诱导的对曼氏血吸虫的抗性并非必不可少。鉴定出两个无反应品系,即P品系和BALB/c品系。P品系小鼠在特异性迟发型超敏反应以及对感染的抗性方面存在缺陷。然而,BALB/c小鼠在受到攻击时未表现出明显的免疫缺陷。这些结果与之前用辐射减毒尾蚴免疫小鼠的研究结果一致,只有一个例外;BALB/c小鼠通过用辐射尾蚴接种疫苗得到保护,但未通过无活性疫苗得到保护。因此,进一步检查本研究中鉴定为高反应和低反应品系的小鼠的免疫反应,应有助于表征无活性疫苗诱导的关键免疫抗性机制,以及这两种对曼氏血吸虫抗性模型中共同起作用的免疫机制。